Zhou Caicun's research has focused on therapies for EGFR-mutated NSCLC and the tumor microenvironment. Notably, Zhou Caicun's significant study published in the New England Journal of Medicine demonstrated that amivantamab combined with chemotherapy, when used as first-line treatment for patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, was more effective than chemotherapy alone [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.